United States - English - NLM (National Library of Medicine)

sanofi pasteur inc. - rabies virus strain pm-1503-3m antigen (propiolactone inactivated) (unii: c4hqf74xmw) (rabies virus strain pm-1503-3m antigen (propiolactone inactivated) - unii:c4hqf74xmw) - rabies virus strain pm-1503-3m antigen (propiolactone inactivated) 2.5 [iu] in 1 ml - imovax rabies is a vaccine indicated for pre-exposure and post-exposure prophylaxis against rabies. imovax rabies vaccine is approved for use in all age groups. physicians must evaluate each possible rabies exposure. local or state public health officials should be consulted if questions arise about the need for prophylaxis. (11) the following factors should be considered before antirabies prophylaxis is initiated. rabid bats have been documented in the 49 continental states, and bats are increasingly implicated as important wildlife reservoirs for variants of rabies virus transmitted to humans. transmission of rabies virus can occur from minor, seemingly underappreciated or unrecognized bites from bats (see table 2). (11) raccoons, skunks, and foxes are the terrestrial carnivores most often infected with rabies in the united states. suggestive clinical signs of rabies among wildlife cannot be interpreted reliably. all bites by such wildlife should be considered possible exposures to rabies virus. post-exposu

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - rabies virus -

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - rabies virus, quantity: 2.5 iu - injection, powder for - excipient ingredients: monopotassium glutamate; trometamol; sodium chloride; disodium edetate; polygeline; sucrose - active immunisation against rabies virus, including a) pre-exposure immunisation b) post-exposure treatment following exposure to rabies virus.

United States - English - NLM (National Library of Medicine)

sanofi pasteur inc. - human rabies virus immune globulin (unii: 95f619atq2) (human rabies virus immune globulin - unii:95f619atq2) - human rabies virus immune globulin 150 [iu] in 1 ml - rabies immune globulin (human) heat treated, imogam rabies – ht, in conjunction with the standard series of rabies vaccine vaccinations, is indicated for individuals suspected of exposure to rabies, particularly severe exposure, with one exception: persons who have been previously immunized with rabies vaccine. previously immunized persons are those who have had a documented rabies virus neutralizing antibody titer and who have completed one of the recommended regimens (pre-exposure or post-exposure) with a cell culture vaccine or another vaccine. administer only vaccine to these persons (i.e., post-exposure for a person previously vaccinated). (1) inject imogam rabies – ht, as promptly as possible after exposure, along with the first dose of vaccine. if initiation of treatment is delayed for any reason, still administer imogam rabies – ht and the first dose of vaccine, regardless of the interval between exposure and treatment. if rabies immune globulin (human) was not administered when vaccination was begun

United States - English - NLM (National Library of Medicine)

natural health supply - rabies virus (unii: i0v66ki1ld) (rabies virus - unii:i0v66ki1ld) - rabies virus 30 [hp_c] - indications: to be used for acute, self-limiting conditions according to standard homeopathic indications.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - rabies, inactivated, whole virus - powder and solvent for solution for injection - rabies, inactivated, whole virus 2.5 iu/ml - rabies, inactivated, whole virus - rabies, inactivated, whole virus - rabipur is indicated for active immunization against rabies in individuals of all ages.

Israel - English - Ministry of Health

sanofi israel ltd - rabies, inactivated, whole virus - powder and solvent for suspension for injection - rabies, inactivated, whole virus 2.5 iu - rabies, inactivated, whole virus - rabies, inactivated, whole virus - prevention of rabies in children and adults. it can be used before and after exposure, as a primary vaccination or as a booster dose.

Ireland - English - HPRA (Health Products Regulatory Authority)

gsk vaccines gmbh - rabies virus (flury lep) inactivated - infus/pdr/oral soln - >= 2.5 international unit(s)/millilitre - rabies vaccines; rabies, inactivated, whole virus

European Union - English - EMA (European Medicines Agency)

zoetis belgium s.a. - canine parainfluenza virus, leptospira and rabies virus. - immunologicals for canidae, live and inactivated viral and bacterial vaccines - dogs - active immunization of dogs from six weeks of age to prevent clinical signs and reduce viral excretion cause by canine parainfluenza virus, to prevent clinical signs, infection and urinary excretion cause by leptospira serovars bratislava, canicola, grippotyphosa and icterohaemorrhagiae and to prevent mortality, clinical signs and infection cause by rabies virus.

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi pasteur - inactivated rabies virus strain pm/wi 38 1503 3m - powder and solvent for suspension for injection - 2.5 international unit(s)/millilitre - rabies vaccines; rabies, inactivated, whole virus